How our consumer strategy is improving quality of life and access to established medicines through innovation
Collaboration: unlocking a new approach to clinical trials
FORTUNE Magazine published its 2016 list of companies that are changing the world, and we are honored to be ranked #1.
More than 35,000 children in the northern Mozambique province of Nampula are now registered with the mVacciNation pilot programme that was rolled out in 2015 by GSK and Vodafone, with funding from GAVI and USAID.
Does the relationship between the pharmaceutical industry and healthcare professionals need to change?
We have made a number of changes to how we interact with healthcare professionals (HCPs), including how we incentivise our pharmaceutical sales representatives, how we support medical education and stopping payments to external HCPs to speak on our behalf about our prescription medicines.
The King’s Fund is a charity focused on improving healthcare in the UK. In partnership with GSK, The King’s Fund manages the annual GSK IMPACT Awards.
Dr Louise Morris says she wants every student at her school to have the education and opportunity to have a career in STEM.
GSK’s President of Pharmaceutical R&D explains why GSK is involved in challenging antibiotics resistance.
Patrick Vallance is something of a rare breed: a game-keeper turned poacher; an academic who's moved over into industry. And not just any industry, but the pharmaceutical industry.
Find out how we are doing more than just giving money.
Find out how we are helping to cut maternal and newborn mortality rates in Kenya.
Explore how we invest in the scientists of the future.
Find out how we will be publicly disclosing information on payments and transfers of value that we make to doctors and other healthcare professionals (HCPs).
We set a target - to achieve ‘zero waste to landfill’ at all our sites by 2020. Already, over 60% of GSK sites and offices have achieved the target.
Andrew Witty, Chief Executive Officer, GSK, discusses antibiotic effectiveness, the issues surrounding drug pricing and corporate inversions. He speaks to Bloomberg's Jonathan Ferro and Hans Nichols on "Countdown" from the World Economic Forum in Davos, Switzerland, January 2016.
Is ‘continuous manufacturing’ the best way to be greener?
We've introduced new manufacturing technologies that will help deliver greater numbers of higher quality medicines more effectively to patients.
What makes GSK’s recently completed transaction with Novartis different?
Putting patients’ interests at the heart of every decision.
Switching a product from a prescription medicine to over the counter (OTC) is nothing to sniff at.
Redefining the shape of GSK and realising significant value for our shareholders.
Reaching hard-to-reach villages which currently represent 70% of India’s 1.2 billion population.
When we analysed our carbon footprint in 2010, two things became clear: we needed to take action to reduce it.
How can you fit six tablets into the same space as four – and why would you want to?
Our scientists aim to discover new medicines while reducing the environmental impact of their manufacture, supply and use.
Studies often employ state-of-the art technology to help scientists and doctors track the effect of a potential new medicine in patients’ bodies.
We have embarked on a pioneering new asthma remission study at the Centre for Therapeutic Target Validation.
In the world of business—and scientific research—war metaphors abound. “Hitting our targets.” “Fighting cancer.” What we don’t see are many comparisons to peacekeeping.
What happened when GSK committed to reinvest 20% of its profits from the least developed countries back into those nations’ healthcare systems?
A functioning immune system is crucial to our health. We have discovered that its role goes beyond such things as keeping colds at bay & fighting infections.
The combination of increased funding, resources and education to fight malaria have contributed to a reduction in deaths from this mosquito-borne disease.
To be the best at what we do, we rely on innovative science to create products capable of transforming the lives of patients.
GSK’s Jon Pender explains why working in partnership was key to addressing the pace of the Ebola outbreak in 2014.
If we can pinpoint a faulty gene and correct it, could we potentially find a way to cure genetic diseases?
Finding new ways to use biosensors and mobile health platforms to improve patient care.
Our VP of east Africa and government affairs, Allan Pamba, explains his desire to improve the health of people in Africa.
Anna Shaw is a Laboratory Analyst apprentice within our manufacturing organisation, based at our Ulverston site.
Patrick Vallance talks about how he went from leading an academic department to his current role heading up our R&D operations.
Danielle Smith is on the Communications Graduate programme and joined GSK in 2012 after graduating from the University of York.
We have a long-standing commitment to data transparency.
One of the more compelling aspects of scientific research is the unexpected avenues down which it can lead.
Learn how the Tres Cantos Open Lab offers top international scientists and academics the opportunity to pursue their own projects as part of an integrated team.
Alicia joined our graduate scheme as an electrical engineer in September 2012.